| Income Statement | 2025-08-31 | |||
|---|---|---|---|---|
| Revenues | 0 | |||
| Research and development expense | 0 | |||
| General and administrative expenses | 271,691 | |||
| Total operating expenses | 271,691 | |||
| Loss from operations | -271,691 | |||
| Capital loss | 0 | |||
| Financial loss, net | 42,285 | |||
| Net (loss) income | -313,976 | |||
| Total comprehensive (loss) income | -313,976 | |||
| Net (loss) per share - basic | 0 | |||
| Net (loss) per share - diluted | 0 | |||
| Weighted average number of shares outstanding - basic | 90,649,474 | |||
| Weighted average number of shares outstanding - diluted | 90,649,474 | |||
CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. (CNBX)